Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.

Right-sided CRC an advantage for liver SIRT

Christina Lau
18 Jul 2017

In patients with liver-only or liver-dominant metastatic colorectal cancer (mCRC) with right-sided primary tumours, addition of selective internal radiation therapy (SIRT) to first-line mFOLFOX6 chemotherapy significantly improves overall survival (OS), according to results of a study presented at the European Society for Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer (WCGC 2017) held in Barcelona, Spain.

Researchers analyzed data from 739 patients enrolled in the SIRFLOX (n=530) and FOXFIRE-Global (n=209) studies. Among 190 patients (24.2 percent) with right-sided primary tumours, OS significantly improved by 36 percent in those who received a single administration of SIRT using yttrium-90 resin microspheres in addition to first-line mFOLFOX6 compared with those who received mFOLFOX6 alone (median, 22 vs 17.1 months; hazard ratio [HR], 0.64; p=0.007). [WCGC 2017, abstract LBA-006]

“However, the addition of SIRT did not confer an improvement in OS in the 540 patients [73.1 percent] with left-sided primary tumours [median, 24.6 months vs 25.6 months for chemotherapy alone; HR, 1.12; p=0.279],” reported investigator Dr Guy van Hazel of the University of Western Australia in Perth, Australia.

The researchers also found a trend for improved progression-free survival (PFS) with the addition of SIRT in patients with right-sided primary tumours (median, 10.8 months vs 8.7 months for chemotherapy alone; HR, 0.73; p=0.053), but not in patients with left-sided primary tumours (median, 11.4 vs 10.8 months; HR, 0.93; p=0.426).

“The incidence of grade ≥3 adverse events did not differ significantly between patients with right-sided or left-sided primary tumours,” van Hazel noted.

In the overall analysis of 739 patients, addition of SIRT to chemotherapy did not lead to improved OS (median, 24.3 vs 24.6 months; p=0.84) or PFS (11.1 vs 10.6 months; p=0.22) vs chemotherapy alone.

“These findings are good news for patients with right-sided primary tumours, who have a much worse prognosis and fewer treatment options than patients with left-sided primary tumours,” van Hazel commented. “We are excited because until now, no treatment has improved the dismal outcome of liver metastases arising from right-sided primary CRC tumours apart from the addition of bevacizumab to chemotherapy.”

According to ESMO spokespersons Dr Dirk Arnold of the Instituto CUF de Oncologia in Lisbon, Portugal and Professor Eric Van Cutsem of the University Hospitals Leuven, Belgium who commented on the study, these findings contribute to recent debates on the biological heterogeneity of colon cancers and tumour localization.

“It remains to be confirmed whether these findings mean that right-sided tumours are more sensitive to SIRT, or whether this is simply related to the fact that the molecular characteristics of right-sided tumours allow fewer treatment options because they have more mutations,” they explained.

In a recent exploratory analysis of the FOXFIRE study, a survival benefit was reported in patients with right-sided primary CRC tumours. [Sharma RA, et al, ASCO 2017, abstract 3507] “Our findings are being validated in the remaining FOXFIRE trial cohort,” said van Hazel.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.